Nventa granted U.S. patent covering heat shock protein fusion to treat anogenital warts
Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,211,411 B2 to Nventa covering the use of HspE7, the Company's investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, to treat patients with anogenital warts. This new U.S. patent covers a method of treating a patient with anogenital warts using a fusion protein comprised of a heat shock protein from the Hsp60 family, which includes Hsp65, and an HPV (type 16) E7 antigen. This patent provides additional patent exclusivity for HspE7 to treat anogenital warts patients through September 2022.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.